Table 4.
Dysglycaemia and type 2 diabetes rates
| Outcomes (metformin; placebo) | Metformin n=71 | Placebo n=73 | Total n=144 |
| 6–13 weeks postnatally | |||
| Any dysglycaemia n (%) | 34/71 (47.9%) | 29/73 (39.7%) | 63 (43.7%) |
| Type 2 diabetes (T2D) since randomisation* | 4 | 4 | 8 |
| Impaired fasting glucose (54; 54) | 4 | 5 | 9 |
| Impaired glucose tolerance (54; 54) | 12 | 12 | 24 |
| High risk of T2D (57; 56) | 19 | 14 | 33 |
| 6 months postnatally | |||
| Any dysglycaemia† n (%) | 8/71 (11.3%) | 8/73 (11.0%) | 16 (11.1%) |
| Type 2 diabetes since randomisation* | 4 | 5 | 9 |
| High risk of T2D (40; 36) | 4 | 3 | 7 |
| 1 year postnatally | |||
| Any dysglycaemia† n (%) | 13/71 (18.3%) | 18/73 (24.7%) | 31 (21.5%) |
| Type 2 diabetes since randomisation* | 5 | 7 | 12 |
| Impaired fasting glucose (15; 17) | 1 | 2 | 3 |
| Impaired glucose tolerance (15; 17) | 4 | 4 | 8 |
| High risk of T2D (15; 18) | 5 | 7 | 12 |
See online supplemental appendix 1 for definitions of terms.
*For the outcome of type 2 diabetes, data are presented cumulatively across all visits.
†T2D at any time point up to this visit, and other dysglycaemia at this time point.